Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × tafasitamab × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lymphoma 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 18 Rituximab 13 Biopsy 13 fludarabine 12 Specimen Handling 10 Prednisone 9 Magnetic Resonance Spectroscopy 9 Lenalidomide 7 venetoclax 6 pembrolizumab 5 obinutuzumab 5 Doxorubicin 5 Vincristine 4 Mycophenolic Acid 4 Bendamustine Hydrochloride 4 trametinib 3 glofitamab 3 fludarabine phosphate 3 copanlisib 3 Whole-Body Irradiation 3 Tacrolimus 3 Methotrexate 3 Etoposide 3 Cytarabine 3 zanubrutinib 2 tocilizumab 2 polatuzumab vedotin 2 palbociclib 2 ibrutinib 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07030699 2026-03-06

ECLAT

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡